Prostate cancer decisions — 2024

The Board denied an effective date prior to July 11, 2014, for the grant of service connection for tension headaches and denied a compensable rating for service-connected tension headaches.

The Board has granted service connection for prostate cancer on an accrued benefits basis, resolving the appeal in favor of the Veteran's surviving spouse.

The Veteran's prostate cancer has been rated at 60 percent since April 19, 2017, and the Board grants an earlier effective date of that rating.

The Veteran's claims for prostate cancer, testicular cancer, and myasthenia gravis have been granted. The Veteran does not qualify for specially adapted housing or special home adaptation grants due to his service-connected disabilities.

The Veteran's service-connected bilateral flat feet have been aggravated, but the current disability is not service connected.,There is no evidence of a diagnosed acquired psychiatric disability during service or linked to service. The claim for paranoid schizophrenia remains denied.,Sleep disturbances are not supported by medical evidence and there is no in-service event or disease.,Prostate cancer and its residuals have not been shown to be related to service, nor can they be attributed to the Veteran's prostate cancer.,Right knee condition has not been linked to service. The claim remains denied.,Back condition has not been linked to service. The claim remains denied.,Left lower extremity varicose veins have not been shown to be related to service. The claim remains denied.,Right lower extremity varicose veins have not been shown to be related to service. The claim remains denied.,Erectile dysfunction is not linked to prostate cancer and the Veteran's service-connected disabilities, so the claim remains denied.,Left knee condition has not been shown to be related to service. The claim remains denied.,Right leg circulation condition has not been shown to be related to service. The claim remains denied.,Bilateral plantar fasciitis has not been shown to be related to service. The claim remains denied.

The Veteran's claims for service connection for prostate cancer and Parkinson's disease are being remanded due to the lack of exposure to herbicide agents during active service. A new medical opinion is needed regarding whether these conditions are related to asbestos exposure.

The Board has granted an earlier effective date of June 24, 2022 for the grant of service connection for PTSD. The appeals for prostate cancer, stroke residuals, and SMC were denied as they are not related to the effective date issue.

The Veteran's claim for an earlier effective date for prostate cancer service connection is denied as there was no prior claim filed. The claim for a higher rating for prostate cancer residuals is granted with a 40 percent evaluation.

The Veteran's service-connected bilateral hearing loss is denied a compensable rating. Service connection for PTSD, anxiety disorder, pelvis cancer, spinal cancer, prostate cancer, hepatitis C, hypertension, cardiovascular disease, ED, and liver condition are all denied.

The Board has remanded the claim of service connection for prostate cancer due to exposure to environmental hazards at Camp Lejeune. The Veteran's lay statements and academic/scientific research regarding a link between his prostate cancer and military service are considered, but an examination is needed to determine if there is a relationship.

The Board has granted earlier effective dates of April 29, 2002 for the grant of service connection for prostate cancer and erectile dysfunction. The Veteran's claims were previously denied in January 2003 due to lack of evidence of herbicide exposure during his service in Thailand.

The Board has determined that the Veteran's service-connected conditions (chronic renal insufficiency, diabetes mellitus with hypertension, and residuals of prostate cancer) contributed substantially or materially to his death.

The Board has remanded the Veteran's claims for prostate cancer, sclerotic lesions of the right hip, and left hip replacement due to potential service connection based on exposure to contaminated water at Camp Lejeune. The AOJ is instructed to consider all submitted evidence and provide a new VA examination to address the etiology of the Veteran's prostate cancer.

The Board has granted the Veteran's claim for service connection for prostate cancer and residuals, finding that his condition is related to his military service at Camp Lejeune.

The Board has granted service connection for prostate cancer based on a presumption of exposure to herbicide agents in Guam, effective October 1, 2022.

The Veteran's prostate cancer residuals, diabetes mellitus, lymphoma, and polyneuropathy have been granted service connection and assigned initial disability ratings. The effective date for the prostate cancer residuals is February 13, 2018.

The Veteran's prostate cancer residuals, diabetes mellitus, lymphoma, and various neuropathies have been granted initial disability ratings. The effective date for service connection for prostate cancer residuals is February 13, 2018.

The Board has remanded two issues: service connection for obstructive sleep apnea and the effective date of prostate cancer. The Veteran's OSA claim is related to his service-connected acquired psychiatric disorders, while his prostate cancer may be due to exposure to smoke pits during his deployment in Iraq.

The Board has granted service connection for prostate cancer and diabetes mellitus, type II (DM II), finding that the Veteran's conditions are related to his in-service exposure to toxic chemicals. The decision is based on positive nexus opinions provided by a private physician.

The Veteran's service connection for bladder cancer and prostate cancer was granted with a 100% rating effective July 13, 2007. The Appellant is not entitled to DIC or survivors' pension due to his age at the time of the Veteran's death.,The Appellant also seeks earlier effective dates for service connection and DEA benefits, but these are denied as there was no indication of a claim prior to July 13, 2007.